Login to Your Account



Elan Looks East with 2 Deals as Royalty Revises Hostile Bid

By Cormac Sheridan
Staff Writer

Wednesday, May 22, 2013
DUBLIN, Ireland – Elan Corp. plc continues to execute its M&A strategy at a dizzying pace, while its would-be acquirer, Royalty Pharma, has tabled a revised offer for the company, worth $12.50 per share or $6.37 billion.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription